Sandoz launches new semaglutide treatment option in Brazil, expanding patient access to GLP-1 medicine in key global market. Sandoz Group AG / Key word(s): Market Launch Sandoz launches new semaglutide treatment option in Brazil, expanding patient access to GLP-1 medicine in key global market 09-Nov-2026 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE * First Sandoz semaglutide launch comes in one of world's largest and fastest-growing GLP-1 markets * More than 16.5 million Brazilians live with diabetes; disease remains key public health challenge in Brazil * Builds on recent milestones including semaglutide regulatory approval in Canada and tirzepatide FDA file acceptance in US Basel, 9 November 2026 - Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, today announces the launch of Owozy(TM)(semaglutide solution for injection) in Brazil, expanding patient access to a new high-quality semaglutide treatment option in one of the world's largest and fastest-growing GLP-1 markets1. Owozy was developed by Adalvo and was approved by the Agência Nacional de Vigilância Sanitária (ANVISA) on 29 July 2026 for the treatment of type-2 diabetes. It will be commercialised in Brazil by local partner Biolab & Co under a distribution and promotion agreement signed earlier this year. Owozy is available in a pre-filled delivery system (multi-dose disposable pen) designed to facilitate use by both patients and healthcare professionals. It is among the earliest new semaglutide treatment options available in Brazil, where the GLP-1 market is valued at an estimated USD 2.7 billion2. Richard Saynor, Sandoz Chief Executive Officer, says: "Our first semaglutide launch marks a historic moment both for Sandoz and for patients in Brazil. Owozy will bring a high-quality treatment option to patients with type-2 diabetes in this major global market, where the disease represents a key public health challenge, while supporting the sustainability of the local healthcare system. It also builds momentum behind our overall GLP-1 strategy and our ambition to be a leading player in the generic GLP-1 market." It is estimated that more than 16.5 million adults in Brazil live with diabetes, including type-2 diabetes, placing the country among those with the highest prevalence worldwide3. In addition, around one in three people with diabetes are still undiagnosed, representing more than five million individuals in Brazil4. Even diagnosed patients face barriers to adequate treatment, reinforcing the need to expand the availability of effective and accessible therapies across the country5. The launch advances the GLP-1 strategy presented at the September 2026 Sandoz Capital Markets Day, including early semaglutide market launches in Brazil and Canada. It also builds on other recent GLP-1 milestones, including regulatory approval for Sandoz(R) Semaglutide (semaglutide) in Canada and US regulatory submission acceptance for in-house development of generic tirzepatide. Overall, it underlines the Sandoz commitment to help millions of patients access generic and biosimilar medicines sustainably and affordably through a global portfolio of more than 1,300 medicines, supported by an industry-leading pipeline of over 300 additional generic programmes. No material financial contribution from the Sandoz launch of semaglutide is expected this year. About Owozy (semaglutide) Owozy is a semaglutide 1.34 mg/mL solution for injection for adults with insufficiently controlled type-2 diabetes mellitus. It is used alongside diet and exercise, either as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in combination with other medicines for the treatment of diabetes. Approved presentations include semaglutide 1.34 mg/mL solution for injection in a 1.5 mL pre-filled pen and semaglutide 1.34 mg/mL solution for injection in a 3.0 mL pre-filled pen. Owozy is administered once weekly, in accordance with the approved product information and medical advice. The available presentations have been developed in accordance with applicable technical requirements and international standards, with consideration for consistent treatment administration, appropriate use, and the needs of adults with type-2 diabetes. DISCLAIMER This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law. REFERENCES 1 Data on file. Based on IQVIA forecast link data, MAT06 2026 2 Data on file. Based on IQVIA analytics link data, MAT09 2026 3 International Diabetes Federation. Brazil: Diabetes country report 2000 - 2050. Available at: Diabetes Data in Brazil | IDF Diabetes Atlas [Last accessed: November 2026] 4 International Diabetes Federation. Brazil: Diabetes country report 2000 - 2050. Available at: Diabetes Data in Brazil | IDF Diabetes Atlas [Last accessed: November 2026] 5 International Diabetes Federation. Brazil: Diabetes country report 2000 - 2050. Available at: Diabetes Data in Brazil | IDF Diabetes Atlas [Last accessed: November 2026] ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 colleagues of 100 nationalities work together to ensure over one billion patients are reached by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 medicines addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. In 2026, Sandoz celebrates 20 years of pioneering biosimilars, 80 years of antibiotics manufacturing and 140 years of heritage. In 2025, Sandoz recorded net sales of USD 11.1 billion. Global Media Relations contacts Investor Relations contacts [email protected] [email protected] Alexis Kalomparis +41 792 790285 Craig Marks +44 7818 942 383 Marina Konrad-Maerk +41 79 487 79 89 Tamara Hackl +41 79 790 5217 Gregor Rodehueser +49 170 574 3200 Silvia Siegfried +41 79 795 9061 End of Inside Information | Language: | English | | Company: | Sandoz Group AG | | / | Centralbahnstrasse 4 | | / | 4051 Basel | | / | Switzerland | | Internet: | www.sandoz.com | | ISIN: | CH1243598427 | | Valor: | 124359842 | | Listed: | SIX Swiss Exchange | | EQS News ID: | 2430278 | | End of Announcement | EQS News Service | 2430278 09-Nov-2026 CET/CEST The discussion is visible to sharewise members.

Sandoz 2026 sales rise 5% at CC as biosimilars climb 19%; core-ebitda margin guidance upgraded to 23.0-23.5%. Published: 29/10/2026 Sandoz 2026 sales reached USD 8,703 million in the first nine months, up 5% at constant currencies (CC) versus the same period of 2025, according to the Sandoz report issued on 28 October 2026. Sandoz (SIX: SDZ; OTCQX: SDZNY), which describes itself as the global leader in affordable medicines, also narrowed its full-year net-sales growth range to 5-6% at CC and upgraded its core-EBITDA margin guidance to 23.0-23.5%. Within Sandoz 2026 sales, the third quarter delivered net sales of USD 2,942 million, a 5% increase at CC and 4% in US dollars. Biosimilar net sales grew 17% at CC to USD 998 million, while generics net sales of USD 1,944 million were stable at CC. Excluding what the company calls the anti-infective business-to-business (B2B) headwind, total Q3 net sales rose 7% at CC and generics grew 2% at CC. Sandoz expects this adverse impact to be immaterial in Q4 2026 and next year, which is a forward-looking statement. Biosimilars represented 34% of Q3 2026 net sales, up from 31% in Q3 2025. North America led the quarter with net-sales growth of 20% at CC, driven by biosimilars. That mix shift is a central feature of Sandoz 2026 sales. Sandoz also used the announcement to point back to its Capital Markets Day, where it unveiled the Bio100 ambition of more than 100 biosimilars in its portfolio by 2040. Sandoz 2026 sales: headline figures for Q3 and the first nine months. For the nine months to 30 September 2026, Sandoz 2026 sales were led by biosimilars, which totalled USD 2,873 million, an increase of 22% in US dollars and 19% at CC. Generics contributed USD 5,830 million, up 2% in US dollars but down 1% at CC. Biosimilars accounted for 33% of the nine-month total, compared with 29% a year earlier, while generics fell to 67% from 71%. The company reports that volumes grew 10% in the period, partly offset by price erosion of 5%. Excluding the anti-infective B2B headwind, Sandoz 2026 sales grew 6% at CC over nine months and generics net sales were stable at CC. The release states that for Q3 and 9M 2026, all growth at CC is the same as the comparable growth rate. The quarterly pattern inside Sandoz 2026 sales shows a steady build through the year. Q1 2026 net sales were USD 2,756 million (up 3% at CC), Q2 reached USD 3,005 million (up 7% at CC), and Q3 added USD 2,942 million. First-half net sales stood at USD 5,761 million, up 5% at CC. Biosimilar growth at CC ran at 18% in Q1, 22% in Q2 and 17% in Q3. For context, Sandoz recorded net sales of USD 11.1 billion in 2025, with Q3 2025 at USD 2,825 million and Q4 2025 at USD 3,029 million. The company's 2025 core-EBITDA margin was 21.7%, the base against which the 2026 margin guidance is now framed. JobFinder Listing The anti-infective B2B headwind has a specific cause. As part of its vertically integrated penicillin production, Sandoz sells active pharmaceutical ingredients to third parties. The release explains that US tariffs imposed in 2025 reduced Chinese exports to the US, and Chinese suppliers then sharply lowered global prices for key penicillin APIs, including 6-Aminopenicillanic acid (6-APA). That price decline coincided with increased global supply. Biosimilar momentum behind Sandoz 2026 sales. Biosimilars are the clearest growth engine in Sandoz 2026 sales. In Europe, the quarter benefitted from the Q4 2025 launches of Afqlir (aflibercept) and Wyost and Jubbonti (denosumab), plus strong performance from Zessly (infliximab). Over nine months, European results also drew on Hyrimoz, Erelzi (etanercept) and Binocrit (epoetin alfa). The company says near-term supply constraints and unfavourable short-term market dynamics in Germany partly offset these gains. International biosimilar growth was underpinned by recent launches of Wyost and Jubbonti and Pyzchiva (ustekinumab), alongside strong contributions from Rixathon (rituximab) and Hyrimoz (adalimumab). In North America, the release attributes excellent biosimilar growth mainly to the June 2025 US launches of Wyost and Jubbonti, together with the performance of Hyrimoz. Generics were more mixed within Sandoz 2026 sales. The release cites unfavourable seasonal effects on antibiotics and over-the-counter cold and cough medicines in Europe earlier in the year, stronger-than-expected short-term pressure in Germany, and active portfolio rationalisation and divestment activity in the International region. International generics were also affected by unfavourable market dynamics in Brazil and Japan, while North America generics benefitted from several successful launches, partly offset by competitive pressure on paclitaxel. Regional performance within Sandoz 2026 sales. Europe remains the largest region in Sandoz 2026 sales, contributing USD 4,647 million or 53% of the nine-month total, up 2% at CC (3% excluding the B2B headwind). In Q3, European net sales were USD 1,521 million, up 1% at CC, with no material anti-infective B2B impact. Sandoz said it has recently increased its European market share, citing IQVIA MIDAS data for Q2 2026 versus Q2 2025. International net sales within Sandoz 2026 sales were USD 2,002 million over nine months, up 1% at CC (2% excluding the headwind), and USD 664 million in Q3, up 1% at CC (5% excluding it). Biosimilars delivered double-digit growth in the nine-month period, driven by Rixathon and the launches of Wyost and Jubbonti and Pyzchiva. North America was the standout in Sandoz 2026 sales. Q3 net sales reached USD 757 million, up 20% at CC (21% excluding the headwind), and nine-month net sales were USD 2,054 million, up 17% at CC. The region accounted for 25% of Q3 net sales and 24% of the nine-month total. Guidance, Bio100 and the outlook after Sandoz 2026 sales. Sandoz now expects full-year 2026 net sales to grow 5-6% at CC, replacing earlier guidance of mid-to-high single-digit growth. The company attributes the change to stronger volume demand in Q3 that created short-term biosimilar supply constraints in Europe and International, and to more challenging temporary conditions in Germany. The core-EBITDA margin is now expected at 23.0-23.5%, against prior guidance of roughly 100 basis points of year-on-year expansion from 21.7%. Sandoz also noted an improved expectation for 2026 core earnings per share. The updated guidance that followed Sandoz 2026 sales excludes unforeseen events and the potential imposition of new US tariffs, and these statements are forward-looking. Sandoz expects no material contribution from generic semaglutide launches this year and anticipates overall pricing to decline by a mid-single-digit percentage in 2026. The update does not change the company's outlook to 2028 or its new outlook to 2030. The strategic backdrop to Sandoz 2026 sales is Bio100. At its September Capital Markets Day in London, Sandoz introduced a 2025-2030 outlook of mid-to-high single-digit compound annual net-sales growth at CC and a core-EBITDA margin of 25-27% by 2030. Through Bio100, it aims to more than double net sales at CC from 2025 to 2035, excluding a significant expected GLP-1 contribution, with a core-EBITDA margin above 30%. CEO Richard Saynor said the pipeline has expanded to 40 assets. Pipeline and capacity moves support that ambition well beyond Sandoz 2026 sales. Sandoz announced a collaboration with Henlius covering up to 10 biosimilar assets, initially cetuximab, evolocumab and belimumab, plus an option for recombinant human hyaluronidase. An agreement with mAbxience adds a proposed emicizumab biosimilar, the first haemophilia medicine in its pipeline. Sandoz opened a high-volume drug-substance centre in Lendava, Slovenia, and plans a new facility in Ljubljana. Sandoz net sales by business, Q3 and 9M 2026 (USD millions). Sandoz net sales by region, Q3 and 9M 2026 (USD millions).

Sandoz experiences biosimilar boom amid supply problems. The generics specialist Sandoz cannot really convince with its figures this time. Not only did it grow less strongly than analysts in the AWP consensus had expected; the adjusted outlook for the financial year is also unconvincing. 28.10.2026 05:49 In the first nine months, revenue rose by 8 percent to 8.7 billion US dollars. At constant exchange rates, this corresponds to an increase of 5 percent. The growth engine was again biosimilars. The cheaper copycat versions of biologic drugs increased by 19 percent to 2.9 billion dollars in the first nine months. The classic generics business, by contrast, barely moved: revenue fell by 1 percent in currency-adjusted terms to 5.8 billion dollars. The division was burdened among other things by the continuing price decline for important penicillin active ingredients. More demand than goods. Especially in biosimilars, a problem became apparent that seems paradoxical at first glance: demand was so strong that Sandoz could not deliver fast enough everywhere. In the third quarter, this led to temporary bottlenecks. In Germany, more difficult market conditions also put pressure on prices. "Demand has significantly exceeded our expectations," Sandoz CEO Richard Saynor said in an interview with AWP. Because the production of biologic drugs must be planned long in advance, Sandoz was unable to ramp up capacity quickly enough despite an expansion. That dampened revenue growth in the short term. In the long term, however, management sees an opportunity in it: more biosimilars sold strengthen the business, especially since these products achieve higher margins. "The faster biosimilars grow, the better it is for us," said CFO Remco Steenbergen. Less revenue, more margin. For the full year, Sandoz now expects currency-adjusted revenue growth of 5 to 6 percent. Previously, the company had held out the prospect of growth in the mid-to-high single-digit percentage range. The main reasons for the adjustment are limited delivery capacity for biosimilars and stronger price pressure in Germany. At the same time, Sandoz raises its target for the core EBITDA margin to 23.0 to 23.5 percent. Previously, the group had held out the prospect of an increase of around one percentage point compared with 21.7 percent in 2025. The reason: the revenue mix is becoming more profitable, and operating business is also running better. The higher margin is intended to more than offset the effect of the somewhat more modest revenue outlook. Penicillin remains a problem child. Saynor is also concerned about price pressure on penicillin. He warns that manufacturing the important antibiotic in Europe is becoming increasingly uneconomical. Political rules for critical medicines are therefore crucial. Without sufficient support, European penicillin production is "seriously at risk," the CEO said. On the stock market, the reaction to the figures is rather muted, as shown by the 2.9 percent share price decline. However, the shares of the SMI newcomer are by far the biggest gainer so far this year. Analysts therefore advise viewing possible setbacks as a buying opportunity in light of a strong long-term growth story.